Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy.

BCL11A HbS RNA interference Sickle cell disease fetal hemoglobin gene therapy hemoglobin switch hemoglobinopathies lentiviral vector shRNAmiR

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
12 Jun 2020
Historique:
received: 08 02 2020
accepted: 12 03 2020
entrez: 18 4 2020
pubmed: 18 4 2020
medline: 18 4 2020
Statut: epublish

Résumé

In this work we provide preclinical data to support initiation of a first-in-human trial for sickle cell disease (SCD) using an approach that relies on reversal of the developmental fetal-to-adult hemoglobin switch. Erythroid-specific knockdown of BCL11A via a lentiviral-encoded microRNA-adapted short hairpin RNA (shRNA

Identifiants

pubmed: 32300607
doi: 10.1016/j.omtm.2020.03.015
pii: S2329-0501(20)30045-0
pmc: PMC7150438
doi:

Types de publication

Journal Article

Langues

eng

Pagination

589-600

Informations de copyright

© 2020 The Authors.

Références

Mol Ther. 2015 Sep;23(9):1465-74
pubmed: 26080908
Br J Haematol. 2007 Nov;139(3):504-7
pubmed: 17910640
Bone Marrow Transplant. 2003 Apr;31(7):547-50
pubmed: 12692619
Blood. 2006 Aug 1;108(3):1073-6
pubmed: 16861353
Nat Genet. 2007 Oct;39(10):1197-9
pubmed: 17767159
Semin Hematol. 2001 Oct;38(4):367-73
pubmed: 11605172
JAMA. 2014 Sep 10;312(10):1033-48
pubmed: 25203083
Am J Med Genet. 1987 Jul;27(3):525-35
pubmed: 2443006
Science. 2008 Dec 19;322(5909):1839-42
pubmed: 19056937
N Engl J Med. 2017 Jul 20;377(3):305
pubmed: 28723338
Blood. 2014 Jan 23;123(4):481-5
pubmed: 24222332
J Clin Invest. 2008 Sep;118(9):3132-42
pubmed: 18688285
Nat Rev Dis Primers. 2018 Mar 15;4:18010
pubmed: 29542687
Science. 2011 Nov 18;334(6058):993-6
pubmed: 21998251
Mol Ther Methods Clin Dev. 2019 Jan 25;13:187-196
pubmed: 30788387
Mol Ther. 2009 Nov;17(11):1919-28
pubmed: 19672245
N Engl J Med. 2009 Jan 29;360(5):447-58
pubmed: 19179314
Nat Immunol. 2003 Jun;4(6):525-32
pubmed: 12717432
Biol Blood Marrow Transplant. 2016 Feb;22(2):207-211
pubmed: 26500093
Nat Med. 2006 Apr;12(4):401-9
pubmed: 16582916
Biol Blood Marrow Transplant. 1996 May;2(2):100-4
pubmed: 9118298
Blood Adv. 2018 Oct 9;2(19):2505-2512
pubmed: 30282642
Science. 1949 Jul 15;110(2846):64-6
pubmed: 17774955
Am J Hematol. 2016 Sep;91(9):931-7
pubmed: 27299299
N Engl J Med. 2002 Apr 18;346(16):1185-93
pubmed: 11961146
Blood. 2011 Aug 4;118(5):1197-207
pubmed: 21628400
Philos Trans R Soc Lond B Biol Sci. 2015 Apr 19;370(1666):
pubmed: 25750242
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1620-5
pubmed: 18245381
Blood. 1985 Jan;65(1):183-9
pubmed: 3965046
Mol Ther Methods Clin Dev. 2019 Apr 04;13:390-398
pubmed: 31024981
N Engl J Med. 2018 Apr 19;378(16):1479-1493
pubmed: 29669226
Mol Ther Nucleic Acids. 2018 Sep 7;12:591-599
pubmed: 30195795
RNA. 2010 Jul;16(7):1328-39
pubmed: 20498457
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5039-43
pubmed: 7685112
Blood. 2011 Nov 10;118(19):5071-9
pubmed: 21885599
Gene Ther. 2004 Jun;11(11):879-81
pubmed: 15057265
Blood. 2006 Oct 15;108(8):2545-53
pubmed: 16825499
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Science. 2013 Aug 23;341(6148):1233151
pubmed: 23845947
Blood. 2017 Mar 16;129(11):1548-1556
pubmed: 27965196
Am J Hematol. 1997 Jan;54(1):40-6
pubmed: 8980259
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
N Engl J Med. 2017 Mar 2;376(9):848-855
pubmed: 28249145
Nat Med. 2019 Feb;25(2):234-241
pubmed: 30664781
J Clin Invest. 1998 Jun 15;101(12):2730-40
pubmed: 9637707
Science. 2009 Nov 6;326(5954):818-23
pubmed: 19892975
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
Hum Gene Ther. 2001 Oct 10;12(15):1893-905
pubmed: 11589831
Sci Transl Med. 2014 Mar 12;6(227):227ra33
pubmed: 24622513
Nature. 2010 Sep 16;467(7313):318-22
pubmed: 20844535
Blood. 2012 Oct 11;120(15):2945-53
pubmed: 22904296
Cell Rep. 2016 Sep 20;16(12):3181-3194
pubmed: 27653684
Blood. 2005 Nov 15;106(10):3639-45
pubmed: 16091448
Mol Ther Methods Clin Dev. 2018 Sep 13;11:9-28
pubmed: 30320151
J Pediatr. 1995 Jun;126(6):896-9
pubmed: 7776091
J Exp Med. 2012 Dec 17;209(13):2467-83
pubmed: 23230003
J Clin Invest. 2016 Oct 3;126(10):3868-3878
pubmed: 27599293
Haematologica. 2011 Jan;96(1):128-33
pubmed: 20935000
Blood. 1993 Mar 1;81(5):1109-23
pubmed: 8443373
Blood. 1994 Nov 1;84(9):3182-8
pubmed: 7524767
Mol Ther Methods Clin Dev. 2018 Nov 01;11:167-179
pubmed: 30533448
Blood. 2011 Jul 7;118(1):19-27
pubmed: 21490337
Mol Ther. 2008 Feb;16(2):378-86
pubmed: 18071333
Biol Blood Marrow Transplant. 2001;7(12):665-73
pubmed: 11787529
Mol Ther. 2020 Jan 8;28(1):328-340
pubmed: 31628051
J Immunol Methods. 1996 Aug 14;194(2):113-9
pubmed: 8765164
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Curr Gene Ther. 2015;15(1):64-81
pubmed: 25429463
EMBO Mol Med. 2010 Aug;2(8):315-28
pubmed: 20665635
Lancet. 2010 Dec 11;376(9757):2018-31
pubmed: 21131035
Hum Gene Ther. 2018 Oct;29(10):1153-1166
pubmed: 30198339
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11869-74
pubmed: 18667698
N Engl J Med. 2017 Oct 26;377(17):1630-1638
pubmed: 28976817
Genes Dev. 1989 Jul;3(7):1019-25
pubmed: 2570734
Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21
pubmed: 20331952
Mol Ther. 2009 Nov;17(11):1929-37
pubmed: 19707188
N Engl J Med. 2010 Jul 22;363(4):355-64
pubmed: 20660403
Blood. 2015 May 28;125(22):3401-10
pubmed: 25824688
Blood. 2003 Dec 15;102(13):4582-93
pubmed: 12933586
N Engl J Med. 2014 Oct 9;371(15):1407-17
pubmed: 25295500
N Engl J Med. 2010 Nov 11;363(20):1918-27
pubmed: 21067383

Auteurs

Christian Brendel (C)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Stem Cell Institute, Cambridge, MA, USA.

Olivier Negre (O)

bluebird bio, Inc., Cambridge, MA, USA.

Michael Rothe (M)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

Swaroopa Guda (S)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Geoff Parsons (G)

bluebird bio, Inc., Cambridge, MA, USA.

Chad Harris (C)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Meaghan McGuinness (M)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Daniela Abriss (D)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Alla Tsytsykova (A)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Denise Klatt (D)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

Martin Bentler (M)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

Danilo Pellin (D)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Lauryn Christiansen (L)

bluebird bio, Inc., Cambridge, MA, USA.

Axel Schambach (A)

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.

John Manis (J)

Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA.

Helene Trebeden-Negre (H)

Connell & O'Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute, Boston, MA, USA.

Melissa Bonner (M)

bluebird bio, Inc., Cambridge, MA, USA.

Erica Esrick (E)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Gabor Veres (G)

bluebird bio, Inc., Cambridge, MA, USA.

Myriam Armant (M)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

David A Williams (DA)

Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Stem Cell Institute, Cambridge, MA, USA.

Classifications MeSH